Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Saad Al-Daama"'
Autor:
Jobran Al Qhtani, Abdulla A Al Harthi, Yousef Katinni, Ahmed Al Barki, Sulaiman Al-Fifi, Asindi A Asindi, Saad Al Daama
Publikováno v:
Nigerian Journal of Paediatrics, Vol 28, Iss 1, Pp 18-20 (2024)
Summary: This case report describes reversible hyperglycaemia in a severely ill six-month old Saudi boy treated with nifedipine for hypertension. Hyperglycaemia became manifest on the second day of treatment with nifedipine and was not dose-related.
Externí odkaz:
https://doaj.org/article/dd08a093deec4a729fb0187c2e518551
Autor:
Khaldoon Aljerian, Waleed AlRajban, Tariq Aljohani, Ali Alshehri, Omar Alsherif, Musa Alharbi, Ibraheem Abosoudah, Wasil Jastaniah, Saad Al Daama, Abdulrahman AlSultan, Nahaa Eid Alsubaie
Publikováno v:
Journal of Nature and Science of Medicine, Vol 7, Iss 2, Pp 122-128 (2024)
Background: The DNA mismatch repair (MMR) is the biological pathway that plays a key role in maintaining genomic stability during DNA replication and recombination. The value of MMR pathway is under investigation in pediatrics' solid tumors. Aims: In
Externí odkaz:
https://doaj.org/article/25ebf1a7003d4e0bbd9c3b60a67d73ea
Autor:
Ibrahim Al-Ghemlas, Saad Al-Daama, Hawazin Aqueel, Khawar Siddiqui, Hassan El-Solh, Hala Omer, Loloah AlRajeh, Amal Al-Seraihy, Ali Alahmari, Hawazen AlSaedi, Awatif AlAnazi, Mouhab Ayas
Publikováno v:
International Journal of Pediatrics and Adolescent Medicine. 9:160-164
Clinical, laboratory and outcome data were reviewed for pediatric patients who were diagnosed with chronic myeloid leukemia (CML) and managed at two tertiary care hospitals in Saudi Arabia, between January 2011 and December 2017 to assess the respons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5575ff4e15fa4606fb77633033c09923
https://doi.org/10.1016/j.ijpam.2022.04.001
https://doi.org/10.1016/j.ijpam.2022.04.001
Autor:
Wasil Jastaniah, Abdulrahman Alsultan, Saad Al Daama, Walid Ballourah, Mohammad Bayoumy, Faisal Al-Anzi, Omar Al Shareef, Mohammed Burhan Abrar, Reem Al Sudairy, Ibrahim Al Ghemlas
Publikováno v:
Journal of Applied Hematology, Vol 8, Iss 2, Pp 41-48 (2017)
Background: Despite the confirmed favorable prognosis of childhood t(8;21) acute myeloid leukemia (AML), recent reports suggest heterogeneity in survival outcomes in this subtype of AML may be influenced by ethnicity. Therefore, we aimed to assess th
Externí odkaz:
https://doaj.org/article/380d6207873040f0abb8ff5051e2295e
Autor:
Amal Alabdulwahab, Hazzaa Alzahrani, Khalid Alsaleh, Fazal Hussain, Mohammed Alshahrani, Abdullah Al-Jefri, Marwan Shaheen, Feras Alfraih, Shahrukh K. Hashmi, Amal Albeihany, Fahad Almohareb, Bassim Albeirouti, Ali Al-Ahmari, Saad Al-Daama, Mahmoud Aljurf, Fahad Alsharif, Mouhab Ayas, Syed Osman Ahmed, Amr Hanbali, Khalid Ibrahim, Hassan El-Solh, Naif Radi Aljohani, Syed Ziauddin A. Zaidi, Hani Alhashmi, Ibraheem Abosoudah, Moheeb Al-Awwami, Ibraheem H. Motabi, Saad Akhtar, Hind Alhumaidan, Naeem Chaudhri, Khalid Ahmed Al-Anazi, Sultan Alotaibi, Amal Al-Seraihy, Walid Rasheed
Publikováno v:
Hematology/Oncology and Stem Cell Therapy, Vol 14, Iss 3, Pp 169-178 (2021)
Saudi Arabia is the largest of the Arabian Gulf countries with a total population of 33.41 million as of 2017. This report summarizes the experience from four leading tertiary care hematopoietic stem cell transplantation (HSCT) centers in Saudi Arabi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c030a0e789a1208ec9554d3ff5b7614
https://doi.org/10.1016/j.hemonc.2020.07.008
https://doi.org/10.1016/j.hemonc.2020.07.008
Autor:
Amal Albeihany, Parvez Ahmed, Lamia Torjemane, Salem Alshemari, Saad Al-Daama, Murtadha Al-Khabori, Wasil Jastaniah, Hasan Hashem, Hani Mawardi, Waleed Da'na, Shahrukh K. Hashmi, David Dennison, Alaa Elhaddad, Syed Sayeed Ahmed, Ahmed Alsaeed, Asma ElQuessar, Bassim Albeirouti, Marwan Shaheen, Fahad Almohareb, Amr Nassar, Naeem Chaudhri, Ahmad Ibrahim, Amal Alabdulwahab, Khalid F. Tabbara, Salam Alkindi, Tariq Mahmood Satti, Salman Naseem Adil, Nour Ben Abdeljelil, Amal Al-Seraihy, Mahmoud Aljurf, Mouhab Ayas, Hassan El Solh
Publikováno v:
Hematology/oncology and stem cell therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17d5470bd0f7c4be72c49ad15a81eec3
https://pubmed.ncbi.nlm.nih.gov/32413418
https://pubmed.ncbi.nlm.nih.gov/32413418
Autor:
Douaa Sayed, Heba Sayed, Saad Al Daama, Heba Raslan, Reema Al-Hayek, Arwa Alsaber, Amany M. Ali, Asmaa M Zahran
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:443-449
Background T-cell acute lymphoblastic leukemia (T-ALL) accounts for about 15% of pediatric ALL. With wider use of intensive chemotherapy, the prognosis for childhood T-ALL has improved. Further gains in treatment outcome will likely require methods t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::650442599399bad5a3b3064aec35de53
https://doi.org/10.1016/j.clml.2017.05.012
https://doi.org/10.1016/j.clml.2017.05.012
Autor:
Walid Ballourah, Ibrahim Ghemlas, Mohammad Bayoumy, Abdulrahman Alsultan, Wasil Jastaniah, Faisal Al-Anzi, Saad Al Daama, Mohammed Burhan Abrar, Omar Al Shareef, Reem Al Sudairy
Publikováno v:
Leukemia Research. 58:48-54
Despite the high incidence of Down syndrome (DS) in Arab countires, the incidence and outcomes of myeloid leukemia of DS (ML-DS) have not been studied. We evaluated 206 pediatric acute myeloid leukemia (AML) patients diagnosed between 2005 and 2012 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa6dcf14d9f0d662e23287bb0f868fce
https://doi.org/10.1016/j.leukres.2017.04.004
https://doi.org/10.1016/j.leukres.2017.04.004
Autor:
Wasil Jastaniah, Walid Ballourah, Ibrahim Ghemlas, Abdulrahman Alsultan, Faisal Al-Anzi, Reem Al Sudairy, Mohammed Burhan Abrar, Saad Al Daama, Omar Al Shareef, Mohamed Bayoumy
Publikováno v:
Clinical lymphoma, myelomaleukemia. 18(12)
Background The outcome of childhood acute myeloid leukemia (AML) in first relapse (rAML) remains poor. Reported overall survival (OS) rates vary between high-income developed countries and those with fewer resources. The OS of rAML in high-income dev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::477ffa38bcaeca95db5e7f1d97f3dd11
https://pubmed.ncbi.nlm.nih.gov/30340992
https://pubmed.ncbi.nlm.nih.gov/30340992
Autor:
Reem Al Sudairy, Mohamed Bayoumy, Mohammed Burhan Abrar, Ibrahim Ghemlas, Omar Al Shareef, Saad Al Daama, Faisal Al-Anzi, Walid Ballourah, Abdulrahman Alsultan, Wasil Jastaniah
Publikováno v:
Hematology (Amsterdam, Netherlands). 23(6)
BACKGROUND Acute promyelocytic leukemia (APL) is a rare form of acute myelogenous leukemia (AML). Survival rates exceed 80% in developed countries. Successful treatments rely on all-trans retinoic acid with anthracycline-based chemotherapy. Availabil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c6e8ec73ea699814e43e21f2d12c3bc
https://pubmed.ncbi.nlm.nih.gov/29212418
https://pubmed.ncbi.nlm.nih.gov/29212418